MCRB Investigation Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Seres Therapeutics, Inc. Assets Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether Seres Therapeutics, Inc.’s (NASDAQ: MCRB) sale of its VOWST microbiome therapeutic business to Société des Produits Nestlé S.A is fair to Seres shareholders.

After the sale was announced, Seres’s stock price fell $0.27 per share or 21% to close at $1.01 per share on August 6, 2024.

Halper Sadeh encourages Seres shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at [phone] or [e-mail] or [e-mail].

On behalf of Seres shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits. We would handle a lawsuit on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.